A phase I study of intravesical camrelizumab for BCG failure Non-Muscle Invasive Bladder Cancer (NMIBC)

被引：0
|
作者：
Wang, Y. [1 ]
Xu, P. H. [1 ]
Bian, X. J. [1 ]
Lu, X. L. [1 ]
Wang, Z. [2 ]
Wang, X. [3 ]
Yao, X. D. [4 ]
Shen, Y. J. [1 ]
Ye, D. Y. [1 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Dept Urol, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Ninth Peoples Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Med, Dept Urol, Shanghai Gen Hosp, Shanghai, Peoples R China
[4] Shanghai Tong Ji Univ, Sch Med, Dept Urol, Shanghai Tenth Peoples Hosp, Shanghai, Peoples R China
来源：
EUROPEAN UROLOGY | 2022年 / 81卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0161
引用
收藏
页码：S251 / S251
页数：1
相关论文
共 50 条
  • [31] Analysis of urinary leukocytes during intravesical immunotherapy with BCG for non-muscle invasive bladder cancer
    Takeda, Yuji
    Kato, Tomoyuki
    Kurota, Yuta
    Ito, Hiromi
    Tsuchiya, Norihiko
    Asao, Hironobu
    CANCER SCIENCE, 2018, 109 : 978 - 978
  • [32] ADJUVANT CANCER PEPTIDE VACCINE TREATMENT WITH INTRAVESICAL BCG THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
    Obara, Wataru
    Hara, Isao
    Miki, Tsuneharu
    Mimata, Hiromitsu
    Shuin, Taro
    Fujioka, Tomoaki
    JOURNAL OF UROLOGY, 2014, 191 (04): : E570 - E570
  • [33] A phase I/II study of EG-70 (detalimogene voraplasmid) intravesical monotherapy for patients (pts) with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)
    Palou, J.
    Marcq, G.
    Steinberg, G.
    Toscone, C.
    Sullivan, J.
    Linback, T.
    Pruthi, R.
    Bryce, R.
    Brown, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S1165 - S1165
  • [34] Which maintenance treatment with intravesical BCG in non-muscle invasive bladder tumors?
    Galliot, Ismael
    Pfister, Christian
    PROGRES EN UROLOGIE, 2011, 21 (01): : F16 - F21
  • [35] Phase 1 study of multi-dose administration of intravesical CG0070 in patients with non-muscle invasive bladder cancer (NMIBC)
    McKiernan, James M.
    Lamm, Donald L.
    Meng, Maxwell V.
    Nemunaitis, John J.
    Arseneau, James C.
    Stephenson, Joe
    Burke, James M.
    Aimi, Junko
    Maslyar, Daniel J.
    JOURNAL OF UROLOGY, 2008, 179 (04): : 616 - 616
  • [36] INTRAVESICAL GEMCITABINE AND DOCETAXOL IN HEAVILY PRE-TREATED PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
    Caruso, Adele
    Ravishankar, Roshan
    VanArsdalen, Keith
    Malkowicz, Stanley
    JOURNAL OF UROLOGY, 2020, 203 : E1124 - E1124
  • [37] Current intravesical therapy for non-muscle invasive bladder cancer
    van Lingen, Anna V.
    Witjes, J. Alfred
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (10) : 1371 - 1385
  • [38] Neoadjuvant Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer
    Messing, Edward M.
    BLADDER CANCER, 2023, 9 (02) : 191 - 192
  • [39] Can presence of granuloma act as a marker of response to intravesical BCG in non-muscle invasive bladder cancer?
    Jallad, S.
    Hughes, P.
    Gupta, A.
    Goubet, S.
    Symes, A.
    Larner, T.
    Thomas, P.
    BJU INTERNATIONAL, 2012, 109 : 36 - 36
  • [40] Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
    Marquette, T.
    Walz, J.
    Rybikowski, S.
    Maubon, T.
    Branger, N.
    Fakhfakh, S.
    Verde, K. L.
    Dermeche, S.
    Gravis, G.
    Pignot, G.
    PROGRES EN UROLOGIE, 2020, 30 (01): : 35 - 40
12345